Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 21, 2024Journal of Oncology Research and TherapyOpen Access

Targeting of the Immune System - From Late-Stage Treatment to Upfront Neoadjuvant Therapy in Non-Small-Cell Lung Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

DRDaniel RosasUniversity of North Carolina at PembrokeMKMin KimCleveland State UniversitySSSpencer StreitRigshospitalet

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Rosas et al. (2024) studied this question.

synapsesocial.com/papers/68e6935fb6db64358761a0d8https://doi.org/10.29011/2574-710x.10217
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immune Checkpoint Inhibitors in Cancer Therapy2022 · 1,376 citations
  2. 2Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer2015 · 9,577 citations
  3. 3Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer2015 · 6,324 citations
  4. 4Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer2018 · 6,779 citations
  5. 5Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy2021 · 104 citations